Dexpanthenol: Difference between revisions

Dexpanthenol
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

VisualWikitext

Latest revision as of 19:47, 18 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Dexpanthenol is a gastrointestinal stimulant that is FDA approved for the prophylaxis of major abdominal surgery to minimize the possibility of paralytic ileus. Common adverse reactions include allergic reactions, Hypotension.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus. Intestinal atony causing abdominal distention; postoperative or postpartum retention of flatus, or postoperative delay in resumption of intestinal motility; paralytic ileus.

Dosage

Prevention of post-operative adynamic ileus: 250 mg (1 mL) or 500 mg (2 mL) intramuscularly. Repeat in 2 hours and then every 6 hours until all danger of adynamic ileus has passed.

Treatment of adynamic ileus: 500 mg (2 mL) intramuscularly. Repeat in 2 hours and then every 6 hours as needed.

Intravenous administration: Dexpanthenol Injection 2 mL (500 mg) may be mixed with bulk I.V. solutions such as glucose or Lactated Ringer’s and slowly infused intravenously.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dexpanthenol in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dexpanthenol in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Dexpanthenol in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dexpanthenol in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dexpanthenol in pediatric patients.

Contraindications

There are no known contraindications to the use of Dexpanthenol Injection.

Warnings

There have been rare instances of allergic reactions of unknown cause during the concomitant use of Dexpanthenol Injection with drugs such as antibiotics, narcotics and barbiturates.

Administration of Dexpanthenol Injection directly into the vein is not advised.

Dexpanthenol Injection should not be administered within one hour of succinylcholine.

Precautions

General

If any signs of a hypersensitivity reaction appear, Dexpanthenol Injection should be discontinued. If ileus is a secondary consequence of mechanical obstruction, primary attention should be directed to the obstruction.

The management of adynamic ileus includes the correction of any fluid and electrolyte imbalance (especially hypokalemia), anemia and hypoproteinemia, treatment of infection, avoidance where possible of drugs which are known to decrease gastrointestinal motility and decompression of the gastrointestinal tract when considerably distended by nasogastric suction or use of a long intestinal tube.

Adverse Reactions

Clinical Trials Experience

There have been a few reports of allergic reactions and single reports of several other adverse events in association with the administration of dexpanthenol. A causal relationship is uncertain. One patient experienced itching, tingling, difficulty in breathing. Another patient had red patches of skin. Two patients had generalized dermatitis and one patient urticaria.

One patient experienced temporary respiratory difficulty following administration of dexpanthenol injection 5 minutes after succinylcholine was discontinued.

One patient experienced a noticeable but slight drop in blood pressure after administration of dexpanthenol while in the recovery room.

One patient experienced intestinal colic one-half hour after the drug was administered.

Two patients vomited following administration and two patients had diarrhea 10 days post-surgery and after Dexpanthenol Injection.

One elderly patient became agitated after administration of the drug.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Dexpanthenol in the drug label.

Drug Interactions

The effects of succinylcholine appeared to have been prolonged in a woman administered dexpanthenol.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C

Animal reproduction studies have not been conducted with Dexpanthenol Injection. It is also not known whether Dexpanthenol Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dexpanthenol Injection should be given to a pregnant woman only if clearly needed.

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dexpanthenol in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dexpanthenol during labor and delivery.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dexpanthenol Injection is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in children have not been established.

Geriatic Use

There is no FDA guidance on the use of Dexpanthenol with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Dexpanthenol with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dexpanthenol with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dexpanthenol in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dexpanthenol in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dexpanthenol in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dexpanthenol in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

There is limited information regarding Monitoring of Dexpanthenol in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Dexpanthenol in the drug label.

Overdosage

There is limited information regarding Overdose of Dexpanthenol in the drug label.

Pharmacology

This image is provided by the Wikipedia.

Mechanism of Action

Pantothenic acid is a precursor of coenzyme A, which serves as a cofactor for a variety of enzyme-catalyzed reactions involving transfer of acetyl groups. The final step in the synthesis of acetylcholine consists of the choline acetylase transfer of acetyl group from acetylcoenzyme A to choline. Acetylcholine is the neurohumoral transmitter in the parasympathetic system and as such maintains the normal functions of the intestine. Decrease in acetylcholine content would result in decreased peristalsis and in extreme cases adynamic ileus. The pharmacological mode of action of the drug is unknown.

Structure

Dexpanthenol is a derivative of pantothenic acid, a B complex vitamin. Dexpanthenol Injection is a sterile, nonpyrogenic, aqueous solution indicated for use as a gastrointestinal stimulant. The chemical name is D-(+)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethybutylamide. The structural formula is:

This image is provided by the National Library of Medicine.

Each mL contains Dexpanthenol 250 mg in Water for Injection q.s. pH (range 4 - 7) may be adjusted with Sodium Citrate and/or Citric Acid.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Dexpanthenol in the drug label.

Pharmacokinetics

Pharmacokinetics data in humans is unavailable.

Nonclinical Toxicology

Carcinogenicity, Mutagenicity, and Impairment of Fertility

There have been no studies in animals to evaluate the carcinogenic, mutagenic, or impairment of fertility potential of dexpanthenol.

Clinical Studies

There is limited information regarding Clinical Studies of Dexpanthenol in the drug label.

How Supplied

Dexpanthenol Injection 250 mg/mL

NDC 0517-0131-25 2 mL Single Dose Vial Packed in boxes of 25

Storage

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)

Images

Drug Images

{{#ask: Page Name::Dexpanthenol |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Ingredients and Appearance

{{#ask: Label Page::Dexpanthenol |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Dexpanthenol in the drug label.

Precautions with Alcohol

Alcohol-Dexpanthenol interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

DEXPANTHENOL®^[1]

Look-Alike Drug Names

There is limited information regarding Dexpanthenol Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ "Dexpanthenol".

[1] "Dexpanthenol".

[1]

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
+|authorTag={{RB}}
+|genericName=Dexpanthenol
 |aOrAn=a
-|indicationType=treatment
+|drugClass=gastrointestinal stimulant
-|hasBlackBoxWarning=Yes
+|indicationType=prophylaxis
-|adverseReactions=<!--Black Box Warning-->
+|indication=[[Abdominal surgery|major abdominal surgery]] to minimize the possibility of [[paralytic ileus]]
+|adverseReactions=[[allergic reactions]], [[Hypotension]]
+<!--Black Box Warning-->
 |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
 |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
-* Content
 <!--Adult Indications and Dosage-->
 <!--FDA-Labeled Indications and Dosage (Adult)-->
-|fdaLIADAdult======Condition1=====
+|fdaLIADAdult=====Indications====
+* Prophylactic use immediately after [[Abdominal surgery|major abdominal surgery]] to minimize the possibility of [[paralytic ileus]]. [[Intestinal atony]] causing [[abdominal distention]]; postoperative or postpartum retention of flatus, or postoperative delay in resumption of [[intestinal motility]]; [[paralytic ileus]].
-* Dosing Information
-:* Dosage
-=====Condition2=====
-* Dosing Information
+====Dosage====
+* Prevention of post-operative adynamic [[ileus]]: 250 mg (1 mL) or 500 mg (2 mL) [[intramuscularly]]. Repeat in 2 hours and then every 6 hours until all danger of [[Ileus|adynamic ileus]] has passed.
-:* Dosage
+* Treatment of adynamic [[ileus]]: 500 mg (2 mL) [[intramuscularly]]. Repeat in 2 hours and then every 6 hours as needed.
-=====Condition3=====
+* [[Intravenous]] administration: Dexpanthenol Injection 2 mL (500 mg) may be mixed with bulk I.V. solutions such as glucose or Lactated Ringer’s and slowly infused intravenously.
-* Dosing Information
+* Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
+|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-:* Dosage
-=====Condition4=====
-* Dosing Information
-:* Dosage
-<!--Off-Label Use and Dosage (Adult)-->
-<!--Guideline-Supported Use (Adult)-->
-|offLabelAdultGuideSupport======Condition1=====
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Non–Guideline-Supported Use (Adult)-->
-|offLabelAdultNoGuideSupport======Condition1=====
+|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Pediatric Indications and Dosage-->
 <!--FDA-Labeled Indications and Dosage (Pediatric)-->
-|fdaLIADPed======Condition1=====
+|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Off-Label Use and Dosage (Pediatric)-->
 <!--Guideline-Supported Use (Pediatric)-->
-|offLabelPedGuideSupport======Condition1=====
+|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Non–Guideline-Supported Use (Pediatric)-->
-|offLabelPedNoGuideSupport======Condition1=====
+|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
+<!--Contraindications-->
+|contraindications=* There are no known contraindications to the use of Dexpanthenol Injection.
-:* Dosage
+<!--Warnings-->
+|warnings=* There have been rare instances of [[allergic reactions]] of unknown cause during the concomitant use of Dexpanthenol Injection with drugs such as [[antibiotics]], [[narcotics]] and [[barbiturates]].
-=====Condition2=====
+* Administration of Dexpanthenol Injection directly into the vein is not advised.
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
+* Dexpanthenol Injection should not be administered within one hour of [[succinylcholine]].
-<!--Contraindications-->
+====Precautions====
-|contraindications=* Condition1
-<!--Warnings-->
+=====General=====
-|warnings=* Description
+* If any signs of a [[hypersensitivity reaction]] appear, Dexpanthenol Injection should be discontinued. If [[ileus]] is a secondary consequence of mechanical obstruction, primary attention should be directed to the [[obstruction]].
-====Precautions====
+* The management of [[Ileus|adynamic ileus]] includes the correction of any fluid and electrolyte imbalance (especially [[hypokalemia]]), [[anemia]] and [[hypoproteinemia]], treatment of infection, avoidance where possible of drugs which are known to decrease [[gastrointestinal motility]] and decompression of the [[gastrointestinal tract]] when considerably distended by nasogastric suction or use of a long intestinal tube.
-* Description
 <!--Adverse Reactions-->
 <!--Clinical Trials Experience-->
-|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
+|clinicalTrials=* There have been a few reports of [[allergic reactions]] and single reports of several other adverse events in association with the administration of dexpanthenol. A causal relationship is uncertain. One patient experienced [[itching]], [[tingling]], [[difficulty in breathing]]. Another patient had red patches of skin. Two patients had [[Dermatitis|generalized dermatitis]] and one patient [[urticaria]].
-=====Body as a Whole=====
-=====Cardiovascular=====
-=====Digestive=====
-=====Endocrine=====
-=====Hematologic and Lymphatic=====
-=====Metabolic and Nutritional=====
-=====Musculoskeletal=====
-=====Neurologic=====
-=====Respiratory=====
-=====Skin and Hypersensitivy Reactions=====
+* One patient experienced temporary [[Dyspnea|respiratory difficulty]] following administration of dexpanthenol injection 5 minutes after [[succinylcholine]] was discontinued.
+* One patient experienced a noticeable but slight [[Hypotension|drop in blood pressure]] after administration of dexpanthenol while in the recovery room.
-=====Special Senses=====
+* One patient experienced [[Colic|intestinal colic]] one-half hour after the drug was administered.
+* Two patients vomited following administration and two patients had [[diarrhea]] 10 days post-surgery and after Dexpanthenol Injection.
+* One elderly patient became agitated after administration of the drug.
-=====Urogenital=====
-=====Miscellaneous=====
-<!--Postmarketing Experience-->
 |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
-=====Cardiovascular=====
-=====Digestive=====
-=====Endocrine=====
-=====Hematologic and Lymphatic=====
-=====Metabolic and Nutritional=====
-=====Musculoskeletal=====
-=====Neurologic=====
-=====Respiratory=====
-=====Skin and Hypersensitivy Reactions=====
-=====Special Senses=====
-=====Urogenital=====
-=====Miscellaneous=====
 <!--Drug Interactions-->
-|drugInteractions=* Drug
+|drugInteractions=* The effects of [[succinylcholine]] appeared to have been prolonged in a woman administered dexpanthenol.
-:* Description
 <!--Use in Specific Populations-->
-|useInPregnancyFDA=* '''Pregnancy Category'''
+|FDAPregCat=C
+|useInPregnancyFDA=* Animal reproduction studies have not been conducted with Dexpanthenol Injection. It is also not known whether Dexpanthenol Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dexpanthenol Injection should be given to a pregnant woman only if clearly needed.
 |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
-|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
+|useInNursing=* It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dexpanthenol Injection is administered to a nursing woman.
-|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
+|useInPed=* Safety and effectiveness in children have not been established.
 |useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 |useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
@@ Line 264: / Line 103: @@
 <!--Administration and Monitoring-->
-|administration=* Oral
+|administration=* [[Intravenous]]
+* [[intramuscular]]
+|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
-* Intravenous
-|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
-* Description
 <!--IV Compatibility-->
@@ Line 275: / Line 113: @@
 <!--Overdosage-->
-|overdose====Acute Overdose===
+|overdose=There is limited information regarding <i>Overdose</i> of {{PAGENAME}} in the drug label.
-====Signs and Symptoms====
+<!--Pharmacology-->
-* Description
+<!--Drug box 2-->
+|drugBox=: [[File:DEXPANTHENOL Wiki Str.png|thumb|none|600px|This image is provided by the Wikipedia.]]
-====Management====
-* Description
+<!--Mechanism of Action-->
+|mechAction=* Pantothenic acid is a precursor of [[coenzyme A]], which serves as a cofactor for a variety of enzyme-catalyzed reactions involving transfer of acetyl groups. The final step in the synthesis of [[acetylcholine]] consists of the choline acetylase transfer of acetyl group from acetylcoenzyme A to choline. [[Acetylcholine]] is the neurohumoral transmitter in the parasympathetic system and as such maintains the normal functions of the intestine. Decrease in acetylcholine content would result in decreased peristalsis and in extreme cases adynamic ileus. The pharmacological mode of action of the drug is unknown.
-===Chronic Overdose===
-There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
-<!--Pharmacology-->
-<!--Drug box 2-->
-|drugBox=<!--Mechanism of Action-->
-|mechAction=*
 <!--Structure-->
-|structure=*
+|structure=* Dexpanthenol is a derivative of pantothenic acid, a B complex vitamin. Dexpanthenol Injection is a sterile, nonpyrogenic, aqueous solution indicated for use as a gastrointestinal stimulant. The chemical name is D-(+)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethybutylamide. The structural formula is:
-: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
+: [[File:DEXPANTHENOL Str.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
+* Each mL contains Dexpanthenol 250 mg in Water for Injection q.s. pH (range 4 - 7) may be adjusted with Sodium Citrate and/or Citric Acid.
 <!--Pharmacodynamics-->
 |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 <!--Pharmacokinetics-->
-|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
+|PK=* Pharmacokinetics data in humans is unavailable.
+|nonClinToxic======Carcinogenicity, Mutagenicity, and Impairment of Fertility=====
-<!--Nonclinical Toxicology-->
+* There have been no studies in animals to evaluate the carcinogenic, mutagenic, or impairment of fertility potential of dexpanthenol.
-|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 <!--Clinical Studies-->
@@ Line 313: / Line 142: @@
 <!--How Supplied-->
-|howSupplied=*
+|howSupplied=* Dexpanthenol Injection 250 mg/mL
-|packLabel=<!--Patient Counseling Information-->
+: NDC 0517-0131-25        2 mL Single Dose Vial        Packed in boxes of 25
+|storage=* Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)
+|packLabel=====PACKAGE LABEL.PRINCIPAL DISPLAY PANEL====
+: [[File:DEXPANTHENOL PDP.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
+====Ingredients and Appearance====
+: [[File:DEXPANTHENOL Ing and App.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
+<!--Patient Counseling Information-->
 |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
@@ Line 321: / Line 159: @@
 <!--Brand Names-->
-|brandNames=* ®<ref>{{Cite web | title =  | url = }}</ref>
+|brandNames=* DEXPANTHENOL®<ref>{{Cite web | title = Dexpanthenol  | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ed47f4b-5182-40b7-a440-9e7b06819d95}}</ref>
 <!--Look-Alike Drug Names-->
-|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
+|lookAlike=
 <!--Drug Shortage Status-->
 |drugShortage=
 }}
-{{PillImage
-|fileName=No image.jpg
-}}
-{{LabelImage
-|fileName={{PAGENAME}}11.png
-}}
-{{LabelImage
-|fileName={{PAGENAME}}11.png
-}}
-<!--Pill Image-->
-<!--Label Display Image-->

Dexpanthenol: Difference between revisions

Latest revision as of 19:47, 18 August 2015

Disclaimer

Overview

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Non–Guideline-Supported Use

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Non–Guideline-Supported Use

Contraindications

Warnings

Precautions

General

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

Drug Interactions

Use in Specific Populations

Pregnancy

Labor and Delivery

Nursing Mothers

Pediatric Use

Geriatic Use

Gender

Race

Renal Impairment

Hepatic Impairment

Females of Reproductive Potential and Males

Immunocompromised Patients

Administration and Monitoring

Administration

Monitoring

IV Compatibility

Overdosage

Pharmacology

Mechanism of Action

Structure

Pharmacodynamics

Pharmacokinetics

Nonclinical Toxicology

Carcinogenicity, Mutagenicity, and Impairment of Fertility

Clinical Studies

How Supplied

Storage

Images

Drug Images

Package and Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Ingredients and Appearance

Patient Counseling Information

Precautions with Alcohol

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

Navigation menu